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Abstract
Background
Early diagnosis of reactivated Chagas disease in HIV patients could be lifesaving. In Latin
America, the diagnosis is made by microscopical detection of the T. cruzi parasite in the
blood; a diagnostic test that lacks sensitivity. This study evaluates if levels of T. cruzi anti-
gens in urine, determined by Chunap (Chagas urine nanoparticle test), are correlated with
parasitemia levels in T. cruzi/HIV co-infected patients.
Methodology/Principal Findings
T. cruzi antigens in urine of HIV patients (N = 55: 31 T. cruzi infected and 24 T. cruzi serology
negative) were concentrated using hydrogel particles and quantified by Western Blot and a
calibration curve. Reactivation of Chagas disease was defined by the observation of para-
sites in blood by microscopy. Parasitemia levels in patients with serology positive for
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Chagas disease were classified as follows: High parasitemia or reactivation of Chagas dis-
ease (detectable parasitemia by microscopy), moderate parasitemia (undetectable by
microscopy but detectable by qPCR), and negative parasitemia (undetectable by micros-
copy and qPCR). The percentage of positive results detected by Chunap was: 100% (7/7)
in cases of reactivation, 91.7% (11/12) in cases of moderate parasitemia, and 41.7% (5/12)
in cases of negative parasitemia. Chunap specificity was found to be 91.7%. Linear regres-
sion analysis demonstrated a direct relationship between parasitemia levels and urine T.
cruzi antigen concentrations (p<0.001). A cut-off of > 105 pg was chosen to determine
patients with reactivation of Chagas disease (7/7). Antigenuria levels were 36.08 times
(95% CI: 7.28 to 64.88) higher in patients with CD4+ lymphocyte counts below 200/mL (p =
0.016). No significant differences were found in HIV loads and CD8+ lymphocyte counts.
Conclusion
Chunap shows potential for early detection of Chagas reactivation. With appropriate adap-
tation, this diagnostic test can be used to monitor Chagas disease status in T. cruzi/HIV co-
infected patients.
Author Summary
Reactivation of Chagas disease in people living with HIV is a serious clinical condition
that is associated with high mortality. Hence, early diagnosis and treatment can be lifesav-
ing. Although there are not well accepted criteria to identify patients at risk of reactivation,
parasitemia levels are usually considered as the best predictor. Microscopy is used in Latin
America for detection of parasitemia levels. However, this has low sensitivity, which usu-
ally leads to a delay in diagnosis and treatment. Quantitative PCR is used only for research
proposes in endemic areas. Antigens in urine (antigenuria) are correlated with parasitemia
levels in animal models, as well as in cases of congenital Chagas disease. We believe that
antigenuria can also be used for prediction of parasitemia levels in T. cruzi/HIV co-
infected patients. In this study, Chunap (Chagas urine nanoparticle test) was used for con-
centration and quantification of T. cruzi antigens in urine of T. cruzi/HIV co-infected
patients. Values of more than 105 pg of T. cruzi antigens in urine were observed only in
patients with reactivation of Chagas disease. This study shows that antigenuria levels are
highly correlated to levels of parasitemia and can be used as a non-invasive technique for
monitoring parasitemia levels in T. cruzi/HIV co-infected patients.
Introduction
Chagas disease, caused by the protozoan Trypanosoma cruzi, affects an estimated 7.8 million
people in the Americas [1]. Similar to HIV infection, Chagas disease is most prevalent in the
adult population [2]. Massive rural-to-urban migration throughout has brought many cases of
chronic Chagas disease into the city where patients are at risk for acquisition of HIV. This has
created conditions for emergence of T. cruzi/HIV co-infection as a significant public health
problem in the Americas.
Bolivia has the highest prevalence of T. cruzi infection in the world; with adult seropreva-
lence figures of up to 30% in urban areas and up to 80–90% in some rural areas [3, 4]. HIV
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infection remains under-diagnosed in Bolivia and there are no data about the epidemiology of
T. cruzi/HIV co-infection in this country.
After infection with T. cruzi, immunocompetent patients enter the acute phase, this phase is
characterized by high parasitemia, mild and nonspecific febrile illness, and, rarely, life-threat-
ening myocarditis and/or meningoencephalitis [5]. After 2 to 3 months, patients pass into the
chronic phase, which is characterized by positive serology but microscopically undetectable
parasitemia. The chronic phase persists life-long in the absence of successful treatment. Many
people in the chronic phase will remain asymptomatic throughout life, but 20% will develop
cardiomyopathy or mega-syndromes of the digestive tract [6]. Chagas disease is usually
acquired during childhood in endemic regions, in contrast to HIV infection [7]. However, the
chronic manifestations are not seen until adulthood.
An estimated 20% of T. cruzi/HIV co-infected individuals develop T. cruzi reactivation. Pre-
sentation includes high levels of parasitemia and severe clinical manifestations; usually involv-
ing CNS syndromes (50–85%) and/or myocarditis (10–55%) [7–12]. Alterations in the CNS
include meningoencephalitis and/or brain accesses that appear very similar, by neuroimaging,
to those produced by Toxoplasma gondii reactivation. As such, direct detection of the parasite
is needed to confirm the diagnosis. Mortality in patients with meningoencephalitis reaches 80–
100%, partly as a consequence of late diagnosis and treatment [7].
Some studies suggest that early diagnosis and treatment with both benznidazole and combi-
nation antiretroviral therapy (cART) could be lifesaving in patients with CNS reactivation [7,
13–14]. However, there are no well accepted criteria to identify patients at risk of reactivation.
Serology is the standard diagnostic modality in the chronic phase, but does not distinguish
between T. cruzi infection with and without reactivation. Current criteria for reactivation are
based on microscopic observation of the parasite in blood, but because of its low sensitivity,
this technique detects reactivation when the parasitemia is high [15]. By this time, symptoms
may be severe and rescue treatment is likely to fail [15, 16]. Furthermore, microscopy requires
extensive training in specimen preparation, and discordant readings by microscopists are fre-
quent. Blood culture and xenodiagnosis have higher sensitivity but take 20–60 days to give con-
clusive results; both are rarely used for diagnosis [15]. Quantitative polymerase chain reaction
(qPCR) has been suggested as a highly efficient method for monitoring levels of parasitemia in
T. cruzi/HIV co-infected patients [15].
The qPCR is used to monitor levels of parasitemia as well as risk of reactivation in immuno-
compromised individuals after organ transplantation in the USA [17,18]. However, in Latin
America, qPCR is not routinely used. A study with T. cruzi/HIV co-infected patients from Bra-
zil demonstrated that the majority of T. cruzi/HIV co-infected patients have substantially
higher parasitemia levels when compared to immunocompetent T. cruzi-infected individuals.
Some of these patients had detectable parasitemia by microscopy even in the absence of symp-
toms [15]. These asymptomatic patients do not appear to have greater short-term mortality,
but they are hypothesized to be at increased risk of developing symptomatic reactivation [15].
High levels of parasitemia may represent an intermediate phase that precedes clinical reacti-
vation. In such circumstances, preemptive treatment may be justified [10, 15]. However, sys-
tematic data on this hypothesis is lacking. Detection of urine T. cruzi antigens has been shown
to correlate with parasitemia levels in animals [19] and could be a convenient, non-invasive
tool to monitor levels of parasitemia in HIV patients. However, antigens in urine exist at very
low concentrations; below the limit of detection of conventional immunoassays. Furthermore,
antigens are masked by highly abundant resident proteins, and are rapidly degraded by endog-
enous and exogenous enzymes [20–25].
A novel nanotechnology based on the use of nano-porous particles that contain high affinity
chemical baits (trypan blue) in the inner core is proposed for concentration and preservation
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of antigens in urine [20–25]. This technology (Chagas urine nanoparticle test, Chunap) has
been applied in the direct diagnosis of congenital Chagas disease with excellent agreement with
standard diagnostic tests [26]. Nano-porous particles are synthetized with poly (N-isopropyl
acrylamide) (pNIPAm) and N,N0-methylenebisacrylamide (BAAm) and coupled with chemi-
cal baits via amidation reaction. The nano-porous structure of the particles performs size siev-
ing, allowing proteins to penetrate inside the particles, depending on their molecular weight
and their dimensional shape. The trypan blue inside the particles captures proteins with
extremely high affinity (KD< 10
−12 M) within minutes [20–26].
A sensitive but relatively simple noninvasive test for monitoring T. cruzi infection in HIV
co-infected is needed. This tool could lead to early treatment and may be lifesaving. In this
study, we demonstrate that levels of T. cruzi antigens determined by Chunap are associated
with levels of parasitemia in T. cruzi/HIV co-infected patients and could be a valuable non-
invasive tool for monitoring Chagas disease reactivation in HIV co-infected patients.
Methods
Ethics statement
The protocols were approved by the institutional review boards of the study hospitals (Hospital
Clínico Viedma, Centro de Vigilancia y Referencia de HIV/AIDS, the Instituto de desarrollo
Humano and the Colectivo de Estudios Aplicados, Desarrollo Social, Salud y Medio ambiente
in Cochabamba, and the Universidad Catolica in Santa Cruz, Bolivia), Asociacion Benefica
Prisma (Lima, Peru) and the Johns Hopkins University (Baltimore, MD).
Human study design
We evaluated 55 samples of HIV patients (31 T. cruzi-infected and 24 T. cruzi uninfected)
from Cochabamba and Santa Cruz, Bolivia. A written informed consent was obtained from all
participants. The diagnosis of HIV infection was performed according to the Bolivian National
Control Program of HIV/AIDS, and was based on detection of specific antibodies by an ELISA
test (Vironostika HIV UNIformII Ag/Ab, Biomerieux) and Western blot (New Lab Blot I,
BioRad). Blood and urine samples were obtained early on in hospitalization and none had
received T. cruzi treatment. Confirmation of T. cruzi infection was based on positive results by
2 or more of the following commercial tests: Chagatest ELISA (Wienner Lab, Rosario- Argen-
tina, sensitivity: 98.81% and specificity: 99.62%), Chagatest ELISA recombinant v 3.0 (Wienner
Lab, Rosario, Argentina; sensitivity: 99.3% and specificity: 98.7%), and the indirect hemaggluti-
nation test (IHA) (PolyChaco. Sensitivity: 98%, Specificity: 99%).
Determination of HIV load and immunosuppression status
Medical records of each participant were reviewed to obtain data on HIV load, CD4+ and CD8+
T-cell counts. Most patients were recently diagnosed with HIV and were not receiving ART at
the time of diagnosis. As a result, high viral loads were observed in patients with and without
Chagas disease (mean: 220969.5 and 84960.6 copy number/ml blood, respectively). We therefore
used a classification of high HIV load as follows: 1)<5000 copies/ml, 2)5000–30 000 copies/
ml, and 3)>30 000 copies/ml [27, 28]. The immunosuppression status was determined by the
levels of CD4+ T-cell counts according to CDC classification system as follow: 1) 200, 2)
201–500 and 3) 500 [29].
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Chagas disease status
Reactivation of T. cruzi infection was determined by detection of circulating parasites by
micromethod. In this technique, blood samples are collected in 4–6 heparinized microhemato-
crit tubes, centrifuged and the buffy coat layer is examined microscopically for parasites [30].
Quantification of the number of copies of DNA of the parasite in blood was performed by
quantitative PCR [31–34]. Patients with Chagas disease were considered to be in one of three
categories according to the levels of parasitemia: High parasitemia or cases with reactivation of
Chagas disease (n = 7, patients with positive micromethod and PCR), moderate parasitemia
(n = 13, patients with positive PCR but negative micromethod) and negative parasitemia
(n = 12, patients with negative PCR but positive by serology).
Pre-analytical handling of urine samples and urinalysis
Patients were asked to provide the first urine of the day before ingestion of liquids, where mid-
stream specimens were collected. Urinalysis was done using urine test strips (Multistik 10 SG,
Siemens, NY-USA). Mean values of urine specific gravity was within normal levels (mean:
1.022, SD: 0.008). Urine samples (10 mL) were immediately centrifuged after collection at 3000
rcf for 10 min and the supernatant was stored in liquid nitrogen or -80°C until use. For antigen
detection the supernatant was adjusted to pH 5–6 with 1M HCl.
Concentration of T. cruzi antigens using hydrogel nano-porous particles
Poly N-isopoprylacrylamide (NIPAm) particles coupled with trypan blue dye (Poly (NIPAm/
TB)) were synthesized as previously described [20–26]. Urine samples (10 mL) were incubated
with 1 mL of poly (NIPAm/TB) particle suspension (7.2 mg/ml dry weight) for 30 min at room
temperature under rotation. Capturing, concentration, and elution of antigens from the parti-
cles was done as previously described [26]. Eluates were mixed with 10 μl of 250 mg/mL treha-
lose (Fluka Chemicals, MO-USA) solution and 10 μl of 1% (v/v) red food dye (McCormick,
MD-USA) in MilliQ water and dried under nitrogen flow (Organomation). Dried eluates were
suspended in 40 μl of SDS sample buffer (50 mM TrisHCl pH 6.8, 2% SDS, 1% 2-mercap-
toethanol, 10% glycerol and 0.02% bromophenol blue). The effective concentration factor is
250 fold based on volumetric ratio (initial volume / final volume = 10000 μl /40 μl).
Determination of levels of T. cruzi antigens by Western blot
Aliquots of 20 μl of re-suspended antigens were heated to 100°C for 7 min. Electrophoresis and
Western Blot analysis of the antigens were performed as previously described [26]. Briefly,
antigens were detected with an anti-T. cruzi lipophosphoglycan (LPG) mouse monoclonal anti-
body (Cedarlane Laboratories USA Inc, NC-USA), diluted 1:250 in PBS with 0.2% I-Block and
0.1% Tween 20. After six washing steps with PBS supplemented with 0.1% Tween 20, antigens
were incubated with peroxidase conjugated goat anti-mouse IgM (Invitrogen Corporation,
CA-USA) diluted 1:5000 in PBS supplemented with 0.2% I-Block and 0.1% Tween 20, for 60
minutes at room temperature. The molecular weight was determined using MagicMark XP
Western Protein Standard (Invitrogen Corporation, CA-USA). Each sample was run twice.
Visualization of antigenic bands was done using an enhanced chemiluminescence system
(Supersignal West Dura, Thermo Fisher Scientific, MA-USA). The trypomastigote excretory-
secretory antigen (TESA) was used to develop a calibration curve. This antigen was harvested
from cell cultures of T. cruzi Y strain in LLC-MK2 cells, as previously described [31]. The cali-
bration curve was established using the following TESA antigen concentrations: 5 pg, 10 pg, 50
pg, 250 pg and 500 pg (R2 = 0.95) (S1 Fig). Antigen levels were determined by densitometry of
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western blots using myImageAnalysis Software (Thermo Scientific, USA) of five specific bands
(22 kDa, 42 kDa, 58 kDa, 75 kDa and 82 kDa) that were detected by Western blot. The limit of
detection of the test in normal urine samples spiked with T. cruzi antigens was 10 pg/ml. The
presence of any of the five diagnostic bands (22 kDa, 42 kDa, 58 kDa, 75 kDa and 82 kDa) was
considered as a positive result. In each experiment we included a negative control (urine sam-
ple of healthy volunteer) and a positive control (10 ml of healthy volunteer urine sample con-
taining 1 ng of TESA antigen). The Chunap was carried out by a laboratory biologist who was
blinded to the Chagas status of the patient.
DNA extraction and qPCR
qPCR was performed to evaluate levels of parasitemia. DNA was purified from 500 μl of blood
clot samples as previously described [32, 33]. The quantification of DNA was determined by
spectrophotometry using a Nanodrop 2000 instrument (Thermo Scientific, Delaware, USA)
and only samples with a ratio of 260nm/280nm of ~1.8 were used for PCR analysis. qPCR was
performed using published methods [34] with the modifications detailed before [35]. The
qPCR was carried out by a laboratory biologist who was blinded to the Chagas status of the
patient.
Statistical analyses
STATA 13 software was used for all statistical analysis. Parasitemia levels determined by qPCR
were evaluated in a logarithmic scale. Differences in mean levels of parasitemia, CD4+ and
CD8+ T cell counts, and HIV load between patients with and without reactivation were evalu-
ated by Student’s t-test with equal and unequal variances. Receiver Operating Characteristic
(ROC) analysis was used to determine the sensitivity and specificity of different cut-offs of anti-
genuria and parasitemia levels for the diagnosis of reactivation of Chagas disease using micros-
copy as gold standard. The association between urine T. cruzi antigen concentration and
parasitemia levels was evaluated using a linear regression model unadjusted and adjusted by
sex, age (years), antiretroviral treatment (yes versus no), HIV load and immune status (CD4
+ and CD8+ T cell counts). The use of a sample size of 31 T. cruzi/HIV co-infected patients
with a significance level of 0.05 gives a statistical power of 72% to determine associations
between levels of antigenuria and parasitemia. This sample size gives a power below 70% to
determine other statistical associations.
Results
Characteristics of patients
The nested-case control study consisted of 55 HIV patients (31 T. cruzi infected and 24 T. cruzi
non-infected). Mean age was 36.8 years (SD: 15.1 years). Mean levels of HIV loads were consid-
erably higher (187387.5 copies/ml, SD: 549436.2 copies/ml) [27, 28], which could be explained
by the short duration of HIV diagnosis (mean: 28.3 months, SD: 24.9 months). Mean levels of
CD4+ cell and CD8+ cell counts were within normal limits according to the CDC classification
(301.3 cells, SD: 226.2 cells, and 765.9 cells, SD: 543.4 cells, respectively) [29]. Tuberculosis was
the most frequent co-infection in these patients (n = 6 cases). Characteristics of patients strati-
fied by Chagas status are shown in Table 1. There were no significant differences in sex, HIV
load, CD4+ cell count, CD8+ cell count, weight, time of HIV diagnosis, and presence of co-
infections. There was however a strong trend for HIV patients co-infected with Chagas to be
older (p = 0.06).
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Performance of Chunap in the diagnosis of Chagas disease
In this study poly (NIPAm)/TB nanoparticles were used to increase the effective sensitivity of
western blot analysis in the detection of T. cruzi antigens by 100 fold as previously described
[26]. Bands of 22 kDa, 42 kDa, 58 kDa, 75 kDa and 82 kDa were detected in nanoparticle-
concentrated urine samples of T. cruzi/HIV co-infected patients (Fig 1). Bands of 22 kDa, 42
kDa and 55 kDa were also detected in 2 (2/24) urine samples of T. cruzi-uninfected/HIV+
patients yielding a specificity of 91.7%. One of these two Chagas negative patients also had a
Table 1. Characteristics of HIV patients in the nested-case control study.
Positive Serology for Chagas Disease Negative Serology for Chagas disease p-value
Sex (n, percentage) 0.92
Female 15 (27.27%) 12 (21.82%)
Male 16 (29.09%) 12 (21.82%)
Age in years (mean, SE) 40.6 (3.6) 31.9 (2.2) 0.06
HIV load in copies/ml (mean, SE) 220969.5 (136363.3) 84960.6 (50325.4) 0.36
Count CD4+ cells (mean, SE) 273.0 (47.4) 337.4 (53.3) 0.37
Count CD8+ cells (mean, SE) 782.1 (121.7) 745.5 (111.0) 0.83
Weight in kg (mean, SE) 59.7 (1.8) 60.3 (2.9) 0.85
Time from HIV diagnosis months (mean, SE) 27.34 (5.1) 29.42 (5.8) 0.79
Co-infections (n, %)a
Total 7 (16.27%) 3 (6.97%) 0.30
Active tuberculosis 4 2
Enteroparasitosis 2 2
Pneumonia 1 0
Malaria 1 0
Herpes Zoster 1 0
Histoplasmosis 0 1
a Some patients showed more than one co-infection during the time of evaluation.
doi:10.1371/journal.pntd.0004407.t001
Fig 1. Antigenic bands in nanoparticles-concentrated urine samples of patients with HIV/T. cruzi co-
infection. Bands were detected byWestern Blot using a monoclonal antibody anti-lipophosphoglycan of T.
cruzi. Bands of 20 kDa, 42 kDa, 58 kDa, 75 kDa, 82 kDa were considered specific for T. cruzi. Bands of other
molecular weight were not considered for diagnosis criteria. Urine samples of T. cruzi+/HIV+ patients: Lanes
1–3, 5, 7, 9, 10–11, 13–14. Urine samples of T. cruzi-/HIV+ patients: Lanes 4, 6, 8, 12, and 15.
doi:10.1371/journal.pntd.0004407.g001
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co-infection withM. tuberculosis. Other bands were also recognized in urine samples of T.
cruzi infected patients, but the specificity was below 60% and were therefore excluded as
potential diagnosis criteria. The percentage of positive results detected by Chunap was 100%
(7/7) among the cases with reactivation or high parasitemia, 91.7% (11/12) among cases with
moderate parasitemia, and 41.7% (5/12) among patients with negative parasitemia (Table 2).
The percentage of T. cruzi-infected patients detected by Chunap, compared to those positive
by microscopy, PCR, and ELISA, was 100% (7/7), 95% (18/19) and 74% (23/31), respectively.
See S1 Diagram.
Chunap and correlation with levels of parasitemia
Mean levels of parasitemia were significantly different between patients with reactivation of
Chagas disease (3.28 logarithm copy number of parasites/ml, 95% CI: 1.56 to 5.00) and patients
without reactivation but with positive qPCR (1.43 logarithm copy number of parasites/ml, 95%
CI: 1.13 to 1.72) (p = 0.003) (Table 3) (Fig 2A). Similarly, mean levels of antigenuria were sig-
nificantly higher in patients with high parasitemia or reactivation of Chagas disease
(mean = 242.21pg, 95% CI: 125.45 to 358.95) compared to patients with moderate parasitemia
(mean = 43.32 pg, 95% CI: 25.06 to 61.58) (p<0.001) (Fig 2B). Using 105 pg as a cut-off, Chu-
nap could detect all patients with reactivation (7/7). The best balance between specificity
(90.62%, 3/29) and sensitivity (71.43%, 5/7) for determination of reactivation by qPCR was
obtained with the cut-off of 2 log (parasites/ml blood), this cut-off was used for categorization
of parasitemia levels in the regression model. High variability of parasitemia levels measured
by qPCR was observed, even in a logarithmic scale.
A linear relationship was observed between antigenuria and parasitemia levels in both the
unadjusted and adjusted regression model (Table 3). Interestingly, when levels of parasitemia
were less than two logarithms, the expected increase in levels of antigenuria was 31.52 pg (95%
CI: 17.04 to 46.01) per each increase in one logarithm of parasitemia (p<0.001, adjusted r2 =
0.84) (Table 3). Similarly, when levels of parasitemia were higher than two logarithms, the
expected increase in antigenuria levels was 106.00 pg (95% CI: 85.13 to 126.85) per each
increase in one logarithm of parasitemia (p<0.001, adjusted r2 = 0.84) (Table 3).
Chunap, host factors and HIV infection
Among patients with Chagas disease, mean levels of CD4+ T-cell counts were significantly
lower in patients with reactivation (131 cells, 95% CI: -56.54–318.54) compared to patients
without reactivation (322.46 cells, 95% CI: 229.45–415.47) (t-test with unequal variances:
p = 0.046) (Fig 3A). Clinical manifestations, parasitemia levels and immunosuppression status
of each patient are shown in Table 4. Among patients with reactivation of Chagas disease, 3
showed clinical manifestations related with Chagas neurological disease, 1 patient had an intes-
tinal perforation, and 3 patients did not show any clinical manifestations. An increase in levels
Table 2. Percentages of positive patients detected by Chunap stratified by levels of parasitemia among HIV/T. cruzi infected patients.
Chunap Micromethod qPCR Serology
Reactivation or high parasitemia (n = 7) 7 (100%) 7 (100%) 7 (100%) 7 (100%)
Moderate parasitemia (n = 12) 11 (91.7%) 0 (0%) 12 (100%) 12 (100%)
Negative parasitemia (n = 12) 5 (41.7%) 0 (0%) 0 (0%) 12 (100%)
Confirmation of T. cruzi infection was based on positive results by 2 or more of serological tests for detection of anti-T. cruzi IgG.
doi:10.1371/journal.pntd.0004407.t002
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of antigenuria of 36.08 pg (95% CI: 7.28 to 64.88, p = 0.016) in patients with< 200 CD4+
T-cell counts was observed in the adjusted linear regression model as compared to patients
with>500 CD4+ T-cell counts (Table 3), but no differences were observed in the unadjusted
model. No statistical associations were observed between antigenuria levels and CD+8 cells
counts, HIV load, and ART in the regression model. There was a trend to lower mean levels of
CD8+ T-cell counts between the two groups (reactivation group = 429.6 cells, Non-reactivation
groups = 838.42 cells, t-test with unequal variances: p = 0.064) (Fig 3B). HIV viral loads were
not statistically significantly different between patients with reactivation (mean: 134,303 cop-
ies/ml, 95% CI: -35,516 to 304,122) and without reactivation (mean: 121,761 copies/ml, 95%
CI: -62,834 to 306,355) (Student’s t-test with unequal variances: p = 0.901).
Discussion
Reactivation of Chagas disease in HIV patients is a serious medical condition, which is often
life-threatening. Early diagnosis of Chagas reactivation and prompt treatment can be life-sav-
ing. However, current methods are based on microscopy that have sub-optimal sensitivity that
do not detect reactivation until parasite loads are very high. A sensitive, non-invasive test is
needed to monitor increase in parasitemia levels and predict risk of reactivation. In this study
we introduce the potential use of a nanoparticle-based tool to monitor T. cruzi infection in
urine of HIV patients.
Table 3. Linear regression model for prediction of levels of antigenuria by levels of parasitemia, and relationship with immune status, HIV load,
sex, age and initiation of antiretroviral therapy.
Unadjusted Adjusted
Coefficient 95% CI p-value Coefficient 95% CI p-value
Log parasitemiaa
< 2.0 31.52 17.04 to 46.01 <0.001 33.65 17.48 to 49.82 <0.001
 2.0 106.00 85.13 to 126.85 <0.001 101.42 79.98 to 122.86 <0.001
CD4 classificationb
>500 cells Reference Reference
200–500 cells -27.63 -94.80 to 39.54 0.412 -0.30 7.28 to 64.88 0.983
< 200 cells 22.37 -45.56 to 90.28 0.511 36.08 7.28 to 64.88 0.016
CD8 classificationc
> 1000 cells Reference Reference
500–1000 cells -4.29 -69.39 to 60.81 0.895 7.71 -20.97 to 36.39 0.550
<500 cells -1.72 -70.67 to 67.23 0.960 12.40 -17.58 to -42.38 0.407
HIV loadd
>30 000 Reference Reference
5000–30 000 -49.83 -107.64 to 7.98 0.089 18.72 -10.06 to 47.50 0.195
< 5000 2.42 -87.47 to 92.31 0.957 36.85 -4.70 to 78.40 0.080
Age (years) -0.27 -2.20 to 1.66 0.782 -1.23 -2.06 to -0.40 0.005
Sex (male versus female) 56.25 5.07 to 107.42 0.032 23.67 -0.87 to 48.21 0.058
ART (yes versus no) -48.43 -100.41 to 3.56 0.067 -0.11 -23.87 to 23.64 0.992
a Logarithm of copy number of parasites/ml blood.
b, c cells/ml of blood,
d Copy number of HIV virus/ml blood.
ART: Antiretroviral treatment.
doi:10.1371/journal.pntd.0004407.t003
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Chagas and HIV infection
No differences were observed in HIV loads, CD4+ cell and CD8+ cell count, and presence of
other co-infections between HIV patients with and without Chagas disease. Among patients
with positive serology for Chagas disease, patients with reactivation of Chagas disease had low
Fig 2. Levels of parasitemia and antigenuria in T. cruzi/HIV co-infected patients. A.) Levels of parasitemia determined by qPCR in T. cruzi/HIV co-
infected patients. B.) Levels of antigenuria determined by Chunap in the three groups of T. cruzi/HIV co-infected patients. Levels of parasitemia: High
parasitemia = positive by PCR and microscopy, Moderate parasitemia = positive by PCR, and negative by microscopy, Negative parasitemia = negative by
PCR and microscopy but positive by serology, and No Chagas = negative by microscopy, PCR and serology. Bottom and top limits of the boxes correspond
to first and third quartiles, and the line inside the boxes represents the second quartile (median). P-values were calculated using T-test with equal variances.
* Statistically significant difference.
doi:10.1371/journal.pntd.0004407.g002
Fig 3. Counts of T-cell CD4+ and T-cell CD8+ in T. cruzi /HIV co-infected patients. (A) T-cell CD4+ and
(B) T-cell CD8+ cells. Bottom and top limits of the boxes correspond to first and third quartiles, and the line
inside the boxes represents the second quartile (median). P-values were calculated using T-test with unequal
variances. * Statistically significant difference.
doi:10.1371/journal.pntd.0004407.g003
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Table 4. Clinical characteristics, antigenuria and parasitemia levels and immunosuppression status of HIV/T. cruzi co-infected patients.
Reactivation cases: detectable parasitemia by microscopy
CODE T-cell CD4+a T-cell CD8+b HIV loadc Chunapd Parasite loade Clinical manifestationsf ARTg Died
1 179 624 83653 432.1 5.6 Transverse myelitis No Yes
2 ND ND ND 396.7 5.4 CNS mass lesions No Yes
3 3 78 237684 255 3.5 None Yes No
4 ND ND ND 108.5 3.4 None No No
5 373 533 15301 142.9 2.9 None No No
6 71 852 17088 172.3 1.1 Meningitis No Yes
7 29 61 317789 188 0.9 Intestinal perforation Yes Yes
Mean 131 429.6 134303 242.2 3.3
SD 151 348.7 136767.1 126.3 1.9
Moderate parasitemia: undetectable parasitemia by microscopy but qPCR positives
CODE T-cell CD4+a T-cell CD8+b HIV loadc Chunapd Parasite loade Clinical manifestationsf ARTg Died
8 231 1033 120282 89.9 3.2 None No No
9 48 426 652536 22.7 2.2 None No No
10 497 ND ND 54.3 2.1 None Yes No
11 ND ND ND 52.4 1.9 None No No
12 132 1615 69402 58.3 1.9 None Yes No
13 659 1527 ND 47.2 1.5 None No No
14 303 1093 7711 19.6 1.4 None No No
15 265 1336 68 42.7 1.4 None Yes No
16 328 898 40 99.9 1.3 None Yes No
17 532 1052 2706 24.9 1.2 None No No
18 168 417 121339 51.3 0.9 None No No
19 383 1052 ND 0 0.9 None Yes No
Mean 322.4 1044.9 121760.5 46.9 1.7
SD 184.1 400.5 220801.3 32.2 0.6
Negative parasitemia: undetectable parasitemia by microscopy and qPCR
CODE T-cell CD4+a T-cell CD8+b HIV loadc Chunapd Parasite loade Clinical manifestationsf ARTg Died
20 125 224 169815 22.3 0 Alterations in EKG Yes No
21 529 778 40 18.4 0 None Yes No
22 848 2000 3235 0 0 None No No
23 99 1352 1 0 0 None Yes No
24 562 ND ND 0 0 None Yes No
25 68 1235 53 27.8 0 Alterations in EKG Yes No
26 563 ND 1576 0 0 None Yes No
27 105 491 3001633 0 0 None Yes No
28 210 562 39227 0 0 None Yes No
29 287 1579 ND 0 0 None Yes No
30 143 589 150 21.5 0 None Yes No
31 108 425 ND 32.3 0 None Yes Yes
Mean 303.9 923.5 357303.3 24.5
SD 256.4 582.9 993176.6 5.5
a, b cells/ml of blood.
c copy number of HIV virus/ml blood.
d pg of T.cruzi antigens.
e Copy number of parasites/ml blood.
f Clinical manifestations related to Chagas disease.
g Antiretroviral treatment.
doi:10.1371/journal.pntd.0004407.t004
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levels of CD4+ T-cells counts compared to patients without reactivation, as previously
observed [15]. The percentage of mortality attributed to Chagas disease was 16.12% (5/31),
which is similar to the reported in longitudinal studies (15.09%, 8/53) [10].
Clinical manifestations related to Chagas disease were observed in the nervous system [7,
10]. In the case of the patient with intestinal perforation we were not able to perform a biopsy
analysis to make the confirmatory diagnosis; however, intestinal perforation is a complication
described in patients with digestive system abnormalities associated with Chagas disease [36].
The presence of asymptomatic reactivation has been previously described and is thought to be
an early stage of Chagas reactivation and a risk factor of HIV progression [10, 37].
Performance of Chunap in the diagnosis of Chagas disease
An IgMmonoclonal antibody against T. cruzi lipophosphoglycan (LPG) was used in this study
for antigen detection. The T. cruzi LPG is a surface glycoconjugate which is composed mainly
of glucosamine, sialic acid and galactosamine in the carbohydrate portion, and of alkylacylpho-
sphatidylinositol in the lipid portion [38]. Although this antigen has been primarily character-
ized in the epimastigote form, it could be an important component of the trypomastigote form,
and could be used during cell recognition, invasion, and immune suppression of the host [38].
This antibody recognizes two bands of 42 kDa and 82 kDa in the trypomastigote secretory-
excretory antigen and crude sonicated trypomastigotes [26].
The percentage of antigenuria positives detected by Chunap (74%) among those with posi-
tive serology is similar to that reported before in chronic infected patients (60%-84%) [39–40].
Two false positive results were found in urine samples of patients with negative serology; one
of whom was also co-infected withM. tuberculosis. We hypothesize that the presence of false
positives could be explained by the existence of other co-infections. In the case of tuberculosis,
the mycobacterial lipoarabinomannan has been detected in urine samples of HIV co-infected
patients [41]. The lipophosphoglycan is also found in other infectious agents such as Leish-
mania, Trichmonas, and Pneumocystis, but the anti-IgM LPG antibody used in this study does
not show cross-reaction with the LPG from Leishmania and Trichomonas species [38]. How-
ever, further studies are needed in order to assess cross-reaction with other parasites that are
commonly present in HIV, such as Toxoplasma gondii, and bacteria and fungi such asM.
tuberculosis and Cryptococcus neoformans.
Chunap and relationship with parasitemia levels
Definition of a parasite load threshold for prediction of reactivation could be used as a guide in
the use of anti-trypanosomal therapy. The early increase in parasitemia may not be symptom-
atic as previously described in one prospective study [10], so monitoring for asymptomatic
parasitemia may permit early detection of reactivation. This could lead to accelerating the initi-
ation of anti-trypanosomal therapy, which could prevent irreversible damage or death.
Levels of parasitemia, determined by qPCR, were higher in patients that had reactivated
Chagas disease than in those without reactivation. However, there was a high variability of
parasitemia levels between individuals. This observation was also reported by a previous study
(mean ± SD in reactivation cases VS non-reactivation: 12,584.96 ± 11,368.35 VS 10.43 ± 3.53,
respectively) [15]. The high variability in parasitemia levels detected by qPCR could be
explained by differences in the strains of T. cruzi, and by the inability to distinguish DNA from
living and dying parasites [15]. Although there was a wide SD found among antigenuria levels,
the variability was less than that seen in parasitemia. This could be explained due to lipopho-
sphoglycan only being excreted by living parasites [38].
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In this study, reactivation was defined as the detection of circulating parasites in blood by
microscopy with or without the presence of clinical manifestations [10]. This definition has
limitations because of the lack of sensitivity and reproducibility of microscopy. As observed by
us and others, patients with positive microscopy could have low levels of parasitemia by qPCR
(and vice-versa), suggesting a poor correlation between microscopy and qPCR. For example, in
the case of patient number 9 in Table 4, the levels of parasitemia and viremia were high, and
the CD4+ counts was low. Yet this patient had undetectable parasitemia by microscopy, thus
not meeting the reactivation criteria. A better definition of Chagas reactivation is needed so
that immunosuppression status and HIV load are also taken into consideration. This will guide
clinicians in case management.
In the guinea pig model of Chagas disease and congenital Chagas disease, the presence of
antigens in urine is correlated with high levels of parasitemia [19, 26]. In this study we dem-
onstrate that antigenuria levels are positively related with parasitemia levels in humans.
Interestingly, the increase in levels of antigenuria was greater among patients with higher
levels of parasitemia (> 2 logarithm copy number parasites/ml). All patients with levels of
antigenuria higher than 105 pg were patients that showed reactivation. In this cross-sectional
study, we have evaluated patients that have reactivated Chagas disease, a longitudinal study
will be necessary to determine a cut-off of antigenuria that predicts reactivation and could be
used in low-resource settings where serial evaluations of samples are logistically difficult
[15].
Chunap and host factors
Antigenuria levels were significantly higher in patients with< 200 CD4+ T-cells, but only in
the adjusted model, suggesting possible confounding effects of HIV loads, treatment, age, and
sex. In contrast to a previous study, we could not find statistically significant differences
between levels of parasitemia or antigenuria, and HIV load and CD8+ T-cells levels [15]. Limi-
tations of this study include possible confounding effects of HIV treatment and the small sam-
ple size. Although we adjusted by the use of ART to make statistical comparisons, we could not
account for the duration of ART. ART drugs have a direct and more immediate effect on HIV
loads as compared to levels of CD4+ T-cells and CD8+ T-cells [15].
Among patients with Chagas disease, young age was found to be a risk factor for high anti-
genuria levels in the adjusted model. However, this association could be influenced by the time
of diagnosis of HIV infection and ART.
The Chunap reached sensitivity levels comparable to the more expensive and time consum-
ing standard of care micromethod and qPCR. The feasibility data presented herein provide evi-
dence that Chunap is a promising tool to improve current Chagas diagnostic algorithm in
clinical settings. Furthermore, in a previous study we demonstrated that Chunap protect T.
cruzi antigens from degradation [26].
In future studies, poly(NIPAm/TB) particles will be magnetized in order to simplify the
clinical diagnostic process and extend accessibility. Sensitivity can be further improved by
increasing the volume of urine analyzed. In conclusion, an antigen urine test for monitoring
Chagas reactivation in HIV patients would be highly desirable for these reasons: a) levels of
antigens in urine are related to levels of parasitemia b) antigenuria levels are less variable com-
pared to levels of parasitemia c) urine is a preferred, less-infectious, non-invasively collected
biological fluid that is more acceptable by patients (especially if continuous samples are
needed), and d) antigen testing can be scaled to a rapid, point of care test that can be performed
in low-equipped laboratories.
Chagas Disease Diagnosis in HIV Patients
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004407 February 26, 2016 13 / 16
Members of the Chagas/HIVWorking Group in Bolivia and Peru
Jean Cabeza, Roni Colanzi, Daniel Lozano, Gonzalo Borda, Gerson Galdos, Lisbeth Ferrufino,
Louisa Messenger, Rosmery Gross, Leny Sanchez, Omar Gandarilla, Maurus Dorn, and Helena
Jahuira.
Supporting Information
S1 Fig. Linear regression and 95% CI for densitometric quantification of trypomastigote
excretory-secretory antigen (TESA) spiked in normal human urine (concentrations 5 pg,
10 pg, 50 pg, 250 pg, 500 pg) and concentrated and detected using Chunap.
(TIF)
S1 Checklist. STARD checklist. Use of Chunap for detection of Chagas disease in T.cruzi/HIV
co-infected patients.
(PDF)
S1 Diagram. STARD diagram. Use of Chunap for detection of Chagas disease in T.cruzi/HIV
co-infected patients.  Confirmation of T. cruzi infection was based on positive results by 2 or
more serological tests for detection of anti- T. cruzi IgG antibodies.  Reactivation of Chagas
disease was based on the detection of circulating parasites by microscopy.
(TIF)
Acknowledgments
Heydi Castro Sesquen and Santiago Saldaña for the administrative assistance, and JB PHU and
Sara D for technical assistance.
The article was partially presented in the 62nd Annual Meeting of the American Society of
Tropical Medicine and Hygiene (ASTMH), November 2013, Washington, D.C. Abstract Num-
ber: 1423.
Author Contributions
Conceived and designed the experiments: YECS RHG CB LL AL. Performed the experiments:
YECS DEC JC CMMJRM JF RC FT EVA. Analyzed the data: YECS RHG CB RCN LL AL NB.
Contributed reagents/materials/analysis tools: RHG CB LL AL RC FT NB. Wrote the paper:
YECS RHG CB DEC JC CMMJRM JF RC FT EVA RCN LL AL NB.
References
1. World Health Assembly. Chagas disease: control and elimination. In: Sixty-third World Health Assem-
bly Resolutions, Geneva, 17–21 May 2010. Resolutions and decisions, annexes (WHA63/2010/REC/
1), resolutionWHA 63. 2010; 20:39–42.
2. UNAIDS/WHO. Global report-UNAIDS report on the global AIDS epidemic 2013. WHO Library Cata-
loguing 2013.
3. Azogue E. Women and congenital Chagas' disease in Santa Cruz, Bolivia: epidemiological and socio-
cultural aspects. Soc Sci Med. 1993; 37:503–11. PMID: 8211262
4. Chippaux JP, Postigo JR, Santalla JA, Schneider D, Brutus L. Epidemiological evaluation of Chagas
disease in a rural area of southern Bolivia. Trans R Soc Trop Med Hyg 2008; 102:578–84. doi: 10.
1016/j.trstmh.2008.03.008 PMID: 18430443
5. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis. 2001; 1:92–100.
PMID: 11871482
6. Rassi A Jr, Rassi A, Little WC. Chagas' heart disease. Clin Cardiol. 2000; 23:883–9. PMID: 11129673
7. Diazgranados CA, Saavedra-Trujillo CH, Mantilla M, Valderrama SL, Alquichire C, Franco-Paredes C.
Chagasic encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical
Chagas Disease Diagnosis in HIV Patients
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004407 February 26, 2016 14 / 16
association. Lancet Infect Dis. 2009; 9:324–30. doi: 10.1016/S1473-3099(09)70088-X PMID:
19393962
8. de Oliveira Santos E, dos Reis Canela J, Gomes Monção HC, Guedes RoqueMJ. Reactivation of Cha-
gas' disease leading to the diagnosis of acquired immunodeficiency syndrome. Braz J Infect Dis. 2002;
6:317–21. PMID: 12585977
9. Sartori AM, Neto JE, Nunes EV, Braz LM, Caiaffa-Filho HH, Oliveira Oda C Jr, et al. Trypanosoma cruzi
parasitemia in chronic Chagas disease: comparison between human immunodeficiency virus (HIV)-
positive and HIV-negative patients. J Infect Dis. 2002; 186:872–5. PMID: 12198628
10. Sartori AM, Ibrahim KY, NunesWestphalen EV, Braz LM, cOliveira OC Jr, Gakiya E, et al. Manifesta-
tions of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann Trop Med Parasi-
tol. 2007; 101:31–50. PMID: 17244408
11. Lazo J, Meneses AC, Rocha A, Ferreira MS, Marquez JO, Chapadeiro E, et al. Chagasic meningoen-
cephalitis in the immunodeficient. Arq Neuropsiquiatr. 1998; 56:93–7. PMID: 9686127
12. Madalosso G, Pellini AC, Vasconcelos MJ, Ribeiro AF, Weissmann L, Oliveira Filho GS, et al. Chagasic
meningoencephalitis: case report of a recently included AIDS-defining illness in Brazil. Rev Inst Med
Trop Sao Paulo. 2004; 46:199–202. PMID: 15361971
13. Bisio M, Altcheh J, Lattner J, Moscatelli G, Fink V, Burgos JM, et al. Benznidazole treatment of chagasic
encephalitis in pregnant woman with AIDS. Emerg Infect Dis. 2013; 19:1490–2. doi: 10.3201/eid1909.
130667 PMID: 23965334
14. Corti M, Yampolsky C. Prolonged survival and immune reconstitution after chagasic meningoencepha-
litis in a patient with acquired immunodeficiency syndrome. Rev Soc Bras Med Trop. 2006; 39:85–8.
PMID: 16501775
15. de Freitas VL, da Silva SC, Sartori AM, Bezerra RC, Westphalen EV, Molina TD, et al. Real-time PCR
in HIV/Trypanosoma cruzi coinfection with and without Chagas disease reactivation: association with
HIV viral load and CD4 level. PLoS Negl Trop Dis. 2011; 5:e1277. doi: 10.1371/journal.pntd.0001277
PMID: 21912712
16. Cordova E, Boschi A, Ambrosioni J, Cudos C, Corti M. Reactivation of Chagas disease with central ner-
vous system involvement in HIV-infected patients in Argentina, 1992–2007. Int J Infect Dis. 2008; 12
(6):587–92. doi: 10.1016/j.ijid.2007.12.007 PMID: 18337139
17. Bern C. Chagas disease in the immunosuppressed host. Curr Opin Infect Dis. 2012; 25:450–7. doi: 10.
1097/QCO.0b013e328354f179 PMID: 22614520
18. Chin-Hong PV, Schwartz BS, Bern C, Montgomery SP, Kontak S, Kubak B, et al. Screening and treat-
ment of Chagas disease in organ transplant recipients in the United States: recommendations from the
chagas in transplant working group. Am J Transplant. 2011; 11:672–80. doi: 10.1111/j.1600-6143.
2011.03444.x PMID: 21401868
19. Castro-Sesquen YE, Gilman RH, Yauri V, Cok J, Angulo N, Escalante H, et al. Detection of soluble anti-
gen and DNA of Trypanosoma cruzi in urine is independent of renal injury in the guinea pig model.
PLoS One. 2013; 8:e58480. doi: 10.1371/journal.pone.0058480 PMID: 23520515
20. Luchini A, Longo C, Espina V, Petricoin EF 3rd, Liotta LA. Nanoparticle technology: addressing the fun-
damental roadblocks to protein biomarker discovery. Curr Mol Med. 2010; 10: 133–41. PMID:
20196732
21. Luchini A, Geho DH, Bishop B, Tran D, Xia C, Dufour RL, et al. Smart hydrogel particles: biomarker har-
vesting: one-step affinity purification, size exclusion, and protection against degradation. Nano letters.
2008; 8: 350–61. PMID: 18076201
22. Douglas TA, Tamburro D, Fredolini C, Espina BH, Lepene BS, Ilag L, et al. The use of hydrogel micro-
particles to sequester and concentrate bacterial antigens in a urine test for Lyme disease. Biomaterials.
2010; 32: 1157–1166. doi: 10.1016/j.biomaterials.2010.10.004 PMID: 21035184
23. Fredolini C, Meani F, Reeder KA, Rucker S, Patanarut A, Botterell PJ, et al. Concentration and Preser-
vation of Very Low Abundance Biomarkers in Urine, such as Human Growth Hormone (hGH), by Ciba-
cron Blue F3G-A Loaded Hydrogel Particles. Nano Res. 2008; 1: 502–518. PMID: 20467576
24. Longo C, Patanarut A, George T, Bishop B, ZhouW, Fredolini C, et al. Core-shell hydrogel particles
harvest, concentrate and preserve labile low abundance biomarkers. PLoS One. 2009; 4: e4763. doi:
10.1371/journal.pone.0004763 PMID: 19274087
25. Tamburro D, Fredolini C, Espina V, Douglas TA, Ranganathan A, Ilag L, et al. Multifunctional core-shell
nanoparticles: discovery of previously invisible biomarkers. J Am Chem Soc. 2011; 133:19178–88.
doi: 10.1021/ja207515j PMID: 21999289
26. Castro-Sesquen YE, Gilman RH, Galdos-Cardenas G, Ferrufino L, Sánchez G, Valencia Ayala E, et al.
Use of a novel chagas urine nanoparticle test (Chunap) for diagnosis of congenital chagas disease.
PLoS Negl Trop Dis. 2014; 8(10):e3211. doi: 10.1371/journal.pntd.0003211 PMID: 25275534
Chagas Disease Diagnosis in HIV Patients
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004407 February 26, 2016 15 / 16
27. Ondoa P, Shamu T, Bronze M, Wellington M, Boender TS, Manting C, et al. Performance and logistical
challenges of alternative HIV-1 virological monitoring options in a clinical setting of Harare, Zimbabwe.
Biomed Res Int. 2014; 2014:102598. doi: 10.1155/2014/102598 PMID: 25025031
28. Bravo IM, Correnti M, Escalona L, Perrone M, Brito A, Tovar V, et al. Prevalence of oral lesions in HIV
patients related to CD4 cell count and viral load in a Venezuelan population. Med Oral Patol Oral Cir
Bucal. 2006; 11(1):E33–9. PMID: 16388291
29. Vajpayee M, Kaushik S, Sreenivas V, Wig N, Seth P. CDC staging based on absolute CD4 count and
CD4 percentage in an HIV-1-infected Indian population: treatment implications. Clin Exp Immuno.
2005; 141:485–90.
30. Freilij H, Muller L, Gonzalez Cappa S M. Direct micromethod for diagnosis of acute and congenital Cha-
gas' disease. J Clin Micro. 1983; 18:327–330
31. Umezawa ES, Nascimento MS, Kesper N Jr, Coura JR, Borges-Pereira J, et al. Immunoblot assay
using excreted-secreted antigens of Trypanosoma cruzi in serodiagnosis of congenital, acute, and
chronic Chagas' disease. J Clin Microbiol. 1996; 34(9): 2143–7. PMID: 8862574
32. Fitzwater S, Calderon M, Lafuente C, Galdos-Cardenas G, Ferrufino L, Verastegui M, et al. Polymerase
chain reaction for chronic Trypanosoma cruzi infection yields higher sensitivity in blood clot than buffy
coat or whole blood specimens. Am J Trop Med Hyg. 2008; 79:768–70. PMID: 18981520
33. Castro-Sesquen YE, Gilman RH, Yauri V, Angulo N, Verastegui M, Velásquez DE, et al. Cavia porcel-
lus as a model for experimental infection by Trypanosoma cruzi. Am J Pathol. 2011; 179:281–8. doi:
10.1016/j.ajpath.2011.03.043 PMID: 21703410
34. Piron M, Fisa R, Casamitjana N, López-Chejade P, Puig L, Vergés M, et al. Development of a real-time
PCR assay for Trypanosoma cruzi detection in blood samples. Acta Trop. 2007; 103: 195–200. PMID:
17662227
35. Bern C, Verastegui M, Gilman RH, Lafuente C, Galdos-Cardenas G, Calderon M, et al. Congenital Try-
panosoma cruzi transmission in Santa Cruz, Bolivia. Clin Infect Dis. 2009; 49:1667–74. doi: 10.1086/
648070 PMID: 19877966
36. Matsuda Nilce Mitiko, Miller Steven M., and Barbosa EvoraI Paulo R.. The Chronic Gastrointestinal
Manifestations of Chagas Disease. Clinics (Sao Paulo). 2009; 64(12): 1219–1224.
37. Sartori AM, Caiaffa-Filho HH, Bezerra RC, do S Guilherme C, Lopes MH, Shikanai-Yasuda MA.
Exacerbation of HIV viral load simultaneous with asymptomatic reactivation of chronic Chagas' dis-
ease. Am J Trop Med Hyg. 2002; 67(5):521–3. PMID: 12479555
38. Singh BN, Lucas JJ, Beach DH, Costello CE. Expression of a novel cell surface lipophosphoglycan-like
glycoconjugate in Trypanosoma cruzi epimastigotes. J Biol Chem. 1994; 269:21972–82. PMID:
8071317
39. Katzin A, Alves MJ, Abuin G, Colli W. Antigenuria in chronic chagasic patients detected by a monoclo-
nal antibody raised against Trypanosoma cruzi. Trans R Soc Trop Med Hyg. 1989; 83(3):341–3. PMID:
2482556
40. Umezawa ES, Shikanai-Yasuda MA, da Silveira JF, Cotrim PC, Paranhos G, Katzin AM. Trypanosoma
cruzi: detection of a circulating antigen in urine of chagasic patients sharing common epitopes with an
immunodominant repetitive antigen. Exp Parasitol. 1993; 76(4):352–7. PMID: 7685708
41. Bjerrum S, Kenu E, Lartey M, NewmanMJ, Addo KK, Andersen AB, et al. Diagnostic accuracy of the
rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV-infected adults in Ghana-
findings from the DETECT HIV-TB study. BMC Infect Dis. 2015; 15(1):407.
Chagas Disease Diagnosis in HIV Patients
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004407 February 26, 2016 16 / 16
